Sign In
Buy AGLE
$12.01
+0 (+0%)
At Close: Feb 26, 2024
Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources
12:56pm, Wednesday, 20'th May 2020
Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources
Find Strong Stocks During the Coronavirus with New Analyst Coverage
11:26pm, Tuesday, 19'th May 2020
Find Strong Stocks During the Coronavirus with New Analyst Coverage
4 Stocks in the Limelight on New Analyst Coverage
02:10pm, Tuesday, 19'th May 2020
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, to
U.S. RESEARCH ROUNDUP-Becton Dickinson, Epam Systems, PayPal Holdings
11:36am, Friday, 08'th May 2020
Wall Street securities analysts on Friday revised their ratings and price targets on several
U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings.
HIGHLIGHTS
Is Aeglea BioTherapeutics (AGLE) Stock a Solid Choice Right Now?
12:41pm, Thursday, 07'th May 2020
Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights
12:30pm, Thursday, 07'th May 2020
Gross Proceeds of $138 Million from April 2020 Public Offering Extends Cash Runway Through 2022 Clinical Trial Application for ACN00177 Approved by MHRA; Progress Toward.
Aeglea BioTherapeutics, Inc. (AGLE) Shares March Higher, Can It Continue?
01:31pm, Wednesday, 06'th May 2020
As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics, Inc. (AGLE).
Anthony Quinn Is The President of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) And They Just Picked Up 44% More Shares
10:19am, Wednesday, 06'th May 2020
Those following along with Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) will no doubt be intrigued by the recent...
Aeglea (AGLE) Upgraded to Strong Buy: What Does It Mean for the Stock?
04:00pm, Tuesday, 05'th May 2020
Aeglea (AGLE) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
08:05pm, Thursday, 30'th Apr 2020
AUSTIN, Texas, April 30, 2020 -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as.
Analysts Are Bullish on Top Healthcare Stocks: Aeglea Biotherapeutics (AGLE), uniQure (QURE)
11:07am, Thursday, 30'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aeglea Biotherapeutics (AGLE) and uniQure (QURE) with
Analysts Are Bullish on Top Healthcare Stocks: Aeglea Biotherapeutics (AGLE), uniQure (QURE)
11:07am, Thursday, 30'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aeglea Biotherapeutics (
AGLE
–
Research Report
) and uniQure (
QURE
–
Research Report
) with bulli
Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering
01:07pm, Tuesday, 28'th Apr 2020
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today
Aeglea BioTherapeutics Announces Proposed Public Offering
08:01pm, Monday, 27'th Apr 2020
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today
